PIRIDE M 2 TAB is a combination of Glimepiride 2 mg and Metformin Hydrochloride 500 mg (sustained release) designed for effective management of Type 2 Diabetes Mellitus. Manufactured by Bluepill Express under certified facilities, this dual-action formulation provides optimal blood glucose control by enhancing insulin secretion and improving insulin sensitivity.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

PIRIDE M 2 TAB is a fixed-dose combination tablet containing Glimepiride 2 mg and Metformin Hydrochloride 500 mg in a sustained-release matrix, specifically developed for the treatment of Type 2 Diabetes Mellitus in adult patients who require improved glycemic control. This formulation offers a balanced therapeutic approach by addressing two key defects in diabetes: impaired insulin secretion and insulin resistance.

Glimepiride, a second-generation sulfonylurea, stimulates pancreatic beta cells to secrete insulin, thereby reducing blood glucose levels effectively. Unlike older sulfonylureas, Glimepiride exerts its effects in a more glucose-dependent manner, helping reduce the risk of hypoglycemia while maintaining potent blood sugar-lowering properties. It also exhibits extrapancreatic actions, such as enhancing glucose uptake in peripheral tissues.

Metformin, a well-established biguanide antidiabetic agent, lowers blood glucose primarily by suppressing hepatic gluconeogenesis, increasing insulin sensitivity in muscle cells, and improving glucose utilization. The sustained-release version used in PIRIDE M 2 TAB allows for prolonged therapeutic levels of Metformin in the bloodstream, minimizing gastrointestinal side effects commonly associated with immediate-release versions.

PIRIDE M 2 TAB is recommended for patients with Type 2 Diabetes who are not adequately controlled with diet, exercise, or monotherapy. It is also suitable for patients who require intensification of treatment. The dual mechanism of action provided by Glimepiride and Metformin works synergistically to control both fasting and postprandial blood sugar levels, supporting better HbA1c outcomes over the long term.

The formulation is optimized for once-daily dosing, typically taken with breakfast or the first major meal of the day to ensure maximum efficacy and tolerability. The convenience of a single tablet reduces pill burden and increases compliance, which is critical for long-term diabetes management. The sustained-release formulation further ensures smooth pharmacokinetic profiles, steady-state glucose control, and better gastrointestinal comfort.

Bluepill Express manufactures PIRIDE M 2 TAB in globally compliant units accredited with WHO-GMP, ISO, and other quality certifications. Each batch is subjected to stringent quality assurance protocols, ensuring stability, uniformity, and therapeutic reliability. The advanced manufacturing processes maintain consistency in drug release profiles, especially for the sustained-release Metformin component, which is essential for predictable clinical outcomes.

PIRIDE M 2 TAB is indicated for adults with Type 2 Diabetes as an adjunct to diet and exercise, especially when monotherapy with either Glimepiride or Metformin alone does not provide sufficient control. It may be initiated in patients with moderate hyperglycemia or as a step-up therapy when transitioning from lower-dose combinations such as PIRIDE M 1 TAB.

This formulation is not intended for use in patients with Type 1 Diabetes, diabetic ketoacidosis, or severe renal or hepatic impairment. Regular monitoring of blood glucose levels, HbA1c, renal function, and vitamin B12 levels (for long-term Metformin use) is advised. PIRIDE M 2 TAB may be used in combination with other oral hypoglycemics or insulin, as clinically indicated by a healthcare professional.

In terms of tolerability, the combination of Glimepiride and Metformin has shown a low incidence of adverse events when used appropriately. Hypoglycemia risk is moderate and is typically related to inadequate calorie intake or drug overdose. Metformin-associated gastrointestinal effects, such as nausea and diarrhea, are minimized through the sustained-release format, making this formulation more patient-friendly.

PIRIDE M 2 TAB is available for third-party manufacturing and global export through Bluepill Express. As part of our turnkey pharmaceutical solutions, we offer complete regulatory documentation including COAs, stability data, bioequivalence support (where applicable), and dossiers prepared for various international markets. Clients can also avail branding support, custom packaging options, and tailored export strategies aligned with local regulatory norms.